Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary Progesterone Therapy for Operable Breast Cancer
NCT00123669Phase 3Completed
- Sponsor
- Tata Memorial Hospital
- Start
- Oct 1997
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of hydroxyprogesterone caproate in breast cancer (2 arms), sponsored by Tata Memorial Hospital. Primary endpoints: Overall Survival at 5 years and Disease-Free Survival at 5 years. Started Oct 1997; status: completed.
02
Drugs
hydroxyprogesterone caproate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00123669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123669.